Expression profile-defined classification of lung adenocarcinoma shows close relationship with underlying major genetic changes and clinicopathologic behaviors.
暂无分享,去创建一个
Takayuki Kosaka | Shuta Tomida | Kiyoshi Yanagisawa | Toshiyuki Takeuchi | Y. Yatabe | T. Mitsudomi | T. Kosaka | S. Tomida | K. Yanagisawa | H. Osada | Takashi Takahashi | Yasushi Yatabe | Tetsuya Mitsudomi | Takashi Takahashi | Hirotaka Osada | T. Takeuchi | Toshiyuki Takeuchi
[1] J. Minna,et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.
[2] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[3] Y. Yatabe,et al. TTF-1 Expression in Pulmonary Adenocarcinomas , 2002, The American journal of surgical pathology.
[4] D. Botstein,et al. Cluster analysis and display of genome-wide expression patterns. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[5] Ash A. Alizadeh,et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.
[6] Yudong D. He,et al. Gene expression profiling predicts clinical outcome of breast cancer , 2002, Nature.
[7] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[8] David E. Misek,et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma , 2002, Nature Medicine.
[9] E. Lander,et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[10] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[11] Masahiro Fukuoka,et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] E. Veldhuizen,et al. Role of pulmonary surfactant components in surface film formation and dynamics. , 2000, Biochimica et biophysica acta.
[13] M. Meyerson,et al. Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[15] Takayuki Kosaka,et al. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Ringnér,et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[17] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[18] Christian A. Rees,et al. Molecular portraits of human breast tumours , 2000, Nature.
[19] David Cella,et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.
[20] Shuta Tomida,et al. Gene expression-based, individualized outcome prediction for surgically treated lung cancer patients , 2004, Oncogene.
[21] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[22] M. Ashburner,et al. Gene Ontology: tool for the unification of biology , 2000, Nature Genetics.
[23] Y. Yatabe,et al. EGFR Mutation Is Specific for Terminal Respiratory Unit Type Adenocarcinoma , 2005, The American journal of surgical pathology.
[24] E. Lander,et al. Gene expression correlates of clinical prostate cancer behavior. , 2002, Cancer cell.
[25] D. Botstein,et al. Diversity of gene expression in adenocarcinoma of the lung , 2001, Proceedings of the National Academy of Sciences of the United States of America.